[1]王桃桃,翟奇辉,鲁张波,等.肺癌患者急性非大面积肺栓塞的影响因素及低分子量肝素联合利伐沙班治疗的临床疗效[J].陕西医学杂志,2025,54(4):519-523.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.017]
　WANG Taotao,ZHAI Qihui,LU Zhangbo,et al.Factors affecting acute non-massive pulmonary embolism in patients with lung cancer and clinical efficacy of low molecular weight heparin combined with rivaroxaban therapy[J].,2025,54(4):519-523.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.017]
点击复制

肺癌患者急性非大面积肺栓塞的影响因素及低分子量肝素联合利伐沙班治疗的临床疗效
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年4期
页码:
519-523
栏目:
临床研究
出版日期:
2025-04-05

文章信息/Info

Title:
Factors affecting acute non-massive pulmonary embolism in patients with lung cancer and clinical efficacy of low molecular weight heparin combined with rivaroxaban therapy
作者:
王桃桃; 翟奇辉; 鲁张波; 庞建芳
(临汾市人民医院呼吸内科,山西 临汾 041081)
Author(s):
WANG Taotao; ZHAI Qihui; LU Zhangbo; PANG Jianfang
(Department of Respiratory Medicine,Linfen People's Hospital,Linfen 041081,China)
关键词:
肺癌;  急性非大面积肺栓塞;  影响因素;  低分子量肝素;  利伐沙班;  临床疗效
Keywords:
Lung cancer;  Acute non-massive pulmonary embolism;  Influencing factors;  Low molecular weight heparin;  Rivaroxaban;  Clinical efficacy
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2025.04.017
文献标志码:
A
摘要:
目的:探究肺癌患者急性非大面积肺栓塞的影响因素及低分子量肝素联合利伐沙班治疗的临床疗效。方法:选取收治的肺癌患者108例展开研究,按患者是否急性非大面积肺栓塞分为对照组与治疗组,各54例,对照组在常规治疗上采用低分子量肝素联合华法林治疗,治疗组采用低分子量肝素联合利伐沙班治疗; 二元Logistic回归分析肺癌患者急性非大面积肺栓塞的影响因素; 比较两组临床疗效、肺通气功能、血气及凝血功能及不良反应差异。结果:以肺癌患者是否出现急性非大面积肺栓塞为因变量,将单因素分析中有统计学意义的纤维蛋白原水平(FIB)、吸烟史、血红蛋白、红细胞比容、D-二聚体水平(D-D)、血氧分压水平(PaO2)、TNM分期为自变量,纳入二元Logistic回归模型,FIB、吸烟史、血红蛋白、D-D、TNM分期均为肺癌患者急性非大面积肺栓塞的影响因素(均P<0.05)。治疗组患者的临床疗效高于对照组。两组治疗后肺通气功能、PT、PO2、PCO2及活化部分凝血活酶时间(APTT)比较差异有统计学意义(均P<0.05)。治疗组不良反应低于对照组,差异无统计学意义(P>0.05)。结论:吸烟、血红蛋白升高及TNM分期高是肺癌患者急性非大面积肺栓塞的影响因素。而联合用药通过抗凝、抗炎等机制显著改善患者肺通气、血气及凝血功能及降低不良反应,为肺癌合并肺栓塞患者提供有效且安全的治疗方案。
Abstract:
Objective:To investigate the influencing factors of acute non-massive pulmonary embolism in lung cancer patients and the clinical efficacy of low molecular weight heparin combined with rivaroxaban treatment.Methods:A study was conducted on 108 lung cancer patients who were admitted to the hospital.They were divided into a control group and a treatment group,with 54 patients in each,based on whether they had acute non-massive pulmonary embolism.The control group received conventional treatment combined with low-molecular-weight heparin and warfarin,while the treatment group received low-molecular-weight heparin combined with rivaroxaban.Binary logistic regression analysis was performed to identify the factors influencing acute non-massive pulmonary embolism in lung cancer patients.The clinical efficacy,pulmonary ventilation function,blood gas and coagulation function,as well as differences in adverse reactions,were compared between the two groups.Results:Using the occurrence of acute non-massive pulmonary embolism in lung cancer patients as the dependent variable,and including fibrinogen level(FIB),smoking history,hemoglobin,hematocrit,D-dimer level(D-D),partial pressure of oxygen(PaO2),and TNM stage as independent variables that were statistically significant in the univariate analysis,we incorporated these into a binary logistic regression model.FIB,smoking history,hemoglobin,D-D,and TNM stage were all found to be influencing factors for acute non-massive pulmonary embolism in lung cancer patients(all P<0.05).The clinical efficacy in the treatment group was higher than that in the control group.There were statistically significant differences between the two groups in pulmonary ventilation function,prothrombin time(PT),partial pressure of oxygen(PO2),partial pressure of carbon dioxide(PCO2),and activated partial thromboplastin time(APTT)after treatment(all P<0.05).The incidence of adverse reactions in the treatment group was lower than that in the control group,although the difference was not statistically significant(P>0.05).Conclusion:Smoking,elevated hemoglobin and high TNM stage are the influencing factors of acute non-massive pulmonary embolism in lung cancer patients.And the combination of drugs significantly improved patients' pulmonary ventilation,blood gas and coagulation function through anticoagulation,anti-inflammatory and other mechanisms,and reduced the adverse effects,providing an effective and safe treatment program for patients with lung cancer combined with pulmonary embolism.

参考文献/References:

[1] VINOD S K,HAU E.Radiotherapy treatment for lung cancer:Current status and future directions[J].Respirology,2020,25(Suppl 2):61-71.
[2] BADE B C,DELA CRUZ C S.Lung cancer 2020:Epidemiology,etiology,and prevention[J].Clin Chest Med,2020,41(1):1-24.
[3] 孙静岚,周红艳,王颖,等.利伐沙班联合阿替普酶治疗急性肺栓塞对患者凝血功能及GRP78 GRP94表达的影响[J].河北医学,2024,30(2):330-335.
[4] 谢函君,邵克武.低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究[J].实用临床医药杂志,2020,24(7):27-30.
[5] 孙军奎,贺连栋,薛兴翠,等.脑心通胶囊联合利伐沙班治疗急性肺栓塞疗效及对IL-6、CRP和TNF-α水平影响[J].中华中医药学刊,2019,37(12):3061-3065.
[6] 杨春华,朱艳华,徐娜,等.低分子肝素联合利伐沙班治疗上消化道出血合并肺栓塞1例[J].江苏医药,2021,47(4):431-432.
[7] YANG H,LIU Y,CHEN L,et al.MiRNA-based therapies for lung cancer:Opportunities and challenges?[J].Biomolecules,2023,13(6):877.
[8] LI Y,WU X,YANG P,et al.Machine learning for lung cancer diagnosis,treatment,and prognosis[J].Genomics Proteomics Bioinformatics,2022,20(5):850-866.
[9] RUIZ-CORDERO R,DEVINE W P.Targeted therapy and checkpoint immunotherapy in lung cancer[J].Surg Pathol Clin,2020,13(1):17-33.
[10] 史梦蓉,张念志,褚文丰,等.基于“少火生气,壮火食气”探讨肺癌病机及治疗[J].陕西中医,2024,45(8):1096-1100.
[11] 陈新,李丹,郭小丽,等.瑞替普酶联合华法林和低分子肝素在高危急性肺栓塞患者中的应用[J].保健医学研究与实践,2024,21(9):24-29.
[12] 段丽娜,徐海樱.利伐沙班对肺栓塞患者的治疗效果及对动脉血氧分压的影响[J].实用临床医药杂志,2020,24(10):85-87,95.
[13] 潘龙飞,孟燕,牛泽群,等.低分子肝素序贯利伐沙班与华法林治疗急性肺栓塞的短期疗效比较研究[J].实用心脑肺血管病杂志,2020,28(10):25-31.
[14] 朱艺欣,刘虎军,左泳泳,等.利伐沙班联合阿替普酶在急性肺栓塞(APTE)急诊治疗中的应用及对患者炎症因子水平的影响[J].贵州医药,2021,45(8):1265-1266.
[15] 贾娟,薛世民,张王锋,等.利伐沙班用于急性肺栓塞的抗凝效果及对血清Hcy、BNP、TnI与D-D水平的影响[J].现代生物医学进展,2019,19(15):2933-2936.
[16] 马微芬.利伐沙班治疗急性肺栓塞的疗效观察及对血管内皮功能的影响[J].中国现代医学杂志,2020,30(9):90-93.
[17] 魏晓辉,孙海凤,苏智祥,等.低分子量肝素钙联合利伐沙班治疗肺癌合并急性肺栓塞的临床疗效及对患者凝血功能和生活质量的影响[J].癌症进展,2022,20(19):1966-1969.
[18] 熊家瑞,黎明江,罗群华.利伐沙班与华法林治疗急性非高危肺血栓栓塞患者的疗效比较[J].广西医学,2019,41(23):3009-3012.
[19] 夏俊涛,李峰,余快,等.利伐沙班、华法林对ACS患者介入治疗后NT-proBNP、D-D及Fg水平的影响[J].分子诊断与治疗杂志,2024,16(6):1130-1133,1142.
[20] 李劲,鲁大胜,周云,等.利伐沙班对急性非高危肺血栓栓塞症患者细胞因子及右心功能的影响[J].实用临床医药杂志,2021,25(7):71-74,80.
[21] 范昌碧,孙娜,陈桂秀,等.甲泼尼龙联合利伐沙班治疗慢性阻塞性肺疾病急性加重期合并肺栓塞的临床疗效[J].西部医学,2019,31(12):1887-1891.
[22] 张安兵,袁小玲,夏秀琼,等.低剂量利伐沙班应用于急性肺栓塞的近期疗效及安全性研究[J].国际呼吸杂志,2022,42(4):275-278.
[23] 赵新春,张翔.利伐沙班治疗急性肺血栓栓塞疗效及对患者血生化指标、右心室功能的影响研究[J].陕西医学杂志,2020,49(7):874-877,880.
[24] 赵新春,张翔.利伐沙班治疗急性肺血栓栓塞疗效及对患者血生化指标、右心室功能的影响研究[J].陕西医学杂志,2020,49(7):874-877,880.
[25] 柴海强.丹红注射液联合利伐沙班治疗急性肺栓塞的临床疗效及其对凝血功能、血管内皮功能、炎性反应的影响[J].实用心脑肺血管病杂志,2019,27(1):70-74.

相似文献/References:

[1]贾丽娟,杜苏丰.重组新城疫病毒疫苗rlRVG对A549荷瘤小鼠瘤体生长的抑制作用[J].陕西医学杂志,2019,(1):6.
　JIA Lijuan,DU Sufeng..The tumor growth influence of recombinant NDV (rlRVG) on lung adenocarcinoma A549transfected in vivo[J].,2019,(4):6.
[2]江茂琼,贾钰铭△,叶文静,等.MDSCs对肺癌小鼠CD8+T细胞及生存期的影响研究[J].陕西医学杂志,2019,(3):293.
　JIANG Maoqiong,JIA Yuming,LI Ting,et al.Effect of MDSCs on CD8 T cells and survival time of lung cancer mice[J].,2019,(4):293.
[3]李君艳,陈国荣.肺癌患者凝血指标与临床特征的关系*[J].陕西医学杂志,2019,(6):718.
　LI Junyan,CHEN Guorong..The relationships between coagulation indicators and clinic characterisitics of patients with lung cancer[J].,2019,(4):718.
[4]王 玲,申 鸿.癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究*[J].陕西医学杂志,2019,(8):1080.
　WANG Ling,SHEN Hong..The value of tumor markers CEA，CA199，CA125，Ang-2，CYFRA211 and AFP in the diagnosis of lung cancer[J].,2019,(4):1080.
[5]韩 乐,陈文娟△,雷光焰,等.microRNA21、microRNA25在肺癌组织中的表达及意义*[J].陕西医学杂志,2019,(12):1596.
　HAN Le,CHEN Wenjuan,LEI Guangyan,et al.Expression and significance of microRNA21 and microRNA25 in lung cancer tissues[J].,2019,(4):1596.
[6]王 勇,张 勇,白正忠△.单操作孔完全胸腔镜与传统三孔胸腔镜治疗老年肺癌疗效对比研究*[J].陕西医学杂志,2019,(12):1670.
[7]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
　CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(4):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
[8]米卫国.负压引流管在单操作孔胸腔镜下肺癌根治术中的临床应用研究[J].陕西医学杂志,2021,50(7):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
　MI Weiguo.Application effect of negative pressure drainage tube in patients undergoing radical surgery for lung cancer under single-port thoracoscopy[J].,2021,50(4):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
[9]张玉琨,李 波,刘 静,等.迷走神经保护对胸腔镜下肺癌根治术后房颤发生的预防作用[J].陕西医学杂志,2021,50(10):1267.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.023]
[10]米 婷,王雅宁.气管镜下宏基因组学二代测序技术在肺癌鉴别诊断中的临床应用价值[J].陕西医学杂志,2022,51(4):437.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.012]

备注/Memo

备注/Memo:
[基金项目]山西省卫生健康委员会科研项目(2022XT661)
更新日期/Last Update: 2025-04-07